PHILADELPHIA - Attendees of the BIO 2005 conference here might have left the event with Amgen Inc.'s name in their heads, caught there like a jingle.

Verus Pharmaceuticals Inc., a company with no technology platform, no products and no plans for R&D, raised total funding of $98 million in its Series A round. (BioWorld Today)